**Where Has All the Nasal Polyposis Gone?**

Ortega-Martin L1*, Betancor D1*, Barroso B1, Valverde-Monge M1, Santillan J2, Villacampa JM1, Sastre J1,3

1Department of Allergy, Fundación Jiménez Díaz, Madrid, Spain
2Department of Otorhinolaryngology, Fundación Jiménez Díaz, Madrid, Spain
3Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain

*Contributed equally as first authors


**Palabras clave:** Pólipos nasales. Poliposis nasal. Eosinófilos. Asma. Hipersensibilidad a antiinflamatorios no esteroideos.

 Nasal polyposis (NP) is a benign chronic inflammatory disease. However, it has a significant impact on quality of life (in particular, the loss of sense of smell), increases socioeconomic burden, and is associated with comorbidities [1]. The exact prevalence of chronic rhinosinusitis with NP (CRSwNP) in the general population is unknown [2]. The objective of this study was to describe the characteristics of patients with NP in a health district of Madrid, Spain.

At our university hospital, we performed a cross-sectional retrospective and observational study through a search of the electronic medical records of patients from our health district based on the terms *nasal polyps* or *nasal polyposis* for the years 2016, 2017, and 2018. We then confirmed that the patients selected had been diagnosed with nasal polyposis based on symptoms and nasal endoscopy [1]. We selected patients who had made at least 1 visit to the outpatient clinic (allergy and ear, nose, and throat [ENT] departments) during the study period. Data collected included patient demographics, presence of atopy based on positive skin test results to common aeroallergens, association with asthma and nonsteroidal anti-inflammatory drug hypersensitivity, use of health care resources such as computed tomography scans, visits/year, and treatment administered (both drugs and surgery). The polyp grading system used was that of Meltzer et al [3]. The Hospital Research Ethics Board approved the study. ENT specialists and allergologists participated in the study, since this condition is often comanaged by both.

Our health area includes 447 600 inhabitants, of whom 393 418 are aged >18 years. The initial search based on the terms used yielded a total of 667 individuals with a confirmed diagnosis of NP; we excluded 272 patients with a confirmed diagnosis of NP because they did not attend the ENT or allergy clinics during the years studied. Therefore, patients with NP in our electronic records accounted for 0.14% of the general population and 0.16% of the population aged >18 years.

A total of 144 new patients fulfilled the criteria consecutively over the 3 years studied (59 in 2016, 53 in 2017, and 32 in 2018). The annual incidence of patients with NP attended in our tertiary hospital was 0.7 to 1.3 per 10 000 (0.013 per 100 in 2016, 0.012 in 2017, and 0.007 in 2018).

The average age at diagnosis was 58.7 years (range, 23-96 years) with a higher prevalence of males (Table). Of 190 patients who underwent endonasal surgery, 66 (34%) were grade 0 in the follow-up.

Other results are summarized in the Table. Although this study was not designed to calculate prevalence or annual incidence, data on NP managed at our tertiary hospital revealed a much lower prevalence of NP than reported in other studies [4-6]. Johansson et al [4] calculated a prevalence of 2.7% (95%CI, 1.9-3.5) with an annual incidence of 1 to 20 per 1000 persons from a random sample of 1900 inhabitants aged >20 years in Sweden diagnosed by nasal endoscopy (compared with 0.07-0.13 per 1000 in our study). A similar prevalence was found in a population in France screened using a validated questionnaire [5]. Our lower results could indicate that NP with minor symptoms and asymptomatic patients with NP do not visit their doctor, as shown by a study of 69 autopsies on patients who died of cardiopulmonary disease or cancer, where NP was found in 32% of autopsies and symptoms of NP were not reported in the medical records [6]. It is also possible that these patients were being managed by general practitioners.

Blood eosinophils in the present sample were relatively high (491.55 [327]), and 35% had >500/µL eosinophils, which means that most had a T2 phenotype [7], as previously observed. As for age of diagnosis, male predominance, and comorbidities, the association with atopy (29%), asthma (45.32%) and hypersensitivity to NSAIDs (13.16%) is consistent with that described in previous studies [1-3,5]. No cases of pediatric NP were diagnosed.

 Remarkably, about half of the patients had undergone functional endoscopic endonasal surgery (FEES), and 51.05% had undergone ≥1 FEES procedure. Of the 190 patients who had undergone ≥1 FEES procedure, NP had recurred in 125 (65.79%) at follow-up visits. Previous data show that about 40% of patients who underwent surgical polypectomy experience recurrences 18 months after surgery [8]; in a Spanish study with 10 years’ follow-up, this figure was 22% [9]. In our study, we recorded a mean follow-up of 3.62 (5.79) years since the previous FEES; the fact that 56% of FEES patients had eosinophilia (>500/µL) could explain the higher recurrence, especially since blood eosinophilia has been associated with infiltration of nasal tissue by eosinophils [10].
As recommended, nasal corticosteroids were the first-line options in the patients we treated. Surprisingly, a significant number of patients abandoned this treatment during the study ($P<.05$). This finding is in line with those of Guo et al [11], who found poor adherence to topical corticosteroids in patients with single recurrences of polyps after surgery, and may reflect a failure of medical care but not a failure of surgery. Interestingly, systemic corticosteroids were used in 40.50% of patients with a mean of 1.82 (1.39) pulses during follow-up. Although a significant decrease in corticosteroid bursts ($P<.05$) was observed, many patients are still exposed to the potential adverse effects of systemic corticosteroids, as NP is a chronic disease. Despite all the treatments used, no significant difference in the polyp scores was observed between the first and last visits ($P=.77$). The main weaknesses of this study are that it is retrospective and single-center.

We highlight that even though prevalence in the general population is approximately 1 and 20 per 1000, most patients with NP do not need specialized care, probably because asymptomatic patients or those who have NP with minor symptoms are not searching for medical care or are not being referred to specialized clinics.

**Funding**

The authors declare that no funding was received for the present study.

**Conflicts of Interest**

J.S. reports having served as a consultant to Thermo Fisher, MEDA, Novartis, Sanoﬁ, Leti, Faes Farma, Mundipharma, and GSK. He has also received lecture fees from Novartis, GSK, Stallergenes, Leti, and Faes Farma and grant support for research from Thermo Fisher, Sanoﬁ, and ALK. The remaining authors declare that they have no conflicts of interest.

**References**

Large Local Reactions to Hymenoptera Stings Negatively Affect Quality of Life to the Same Degree as Systemic Reactions

Sánchez-Morillas L1, Alfaya Arias T2, Martínez San Ireneo M3, Domínguez Noche C4, Vega Gutierrez JM5, Vega Castro A6, Moreno Mata E7, Marqués L8, Fuentes Ferrer M9, Ruiz-León B10 (Hymenoptera Allergy Committee of the SEAIC)

1Allergy Department, Hospital Universitario Clínico San Carlos, IdISSC, ARADyAL RD16/0006/0009 Madrid, Spain
2Allergy Department, Hospital General Universitario de Ciudad Real, Hospital Universitario Fundación Alcorcón, Spain
3Allergy Department, Hospital Virgen del Valle, Toledo, Spain
4Allergy Department, Hospital Virgen del Puerto, Plasencia, Spain
5Allergy Department, Hospital Universitario Río Hortega, Valladolid, Spain
6Allergy Department, Hospital Universitario de Guadalajara, Spain, ARADyAL Spanish Thematic Network and Co-operative Research Center RD16/0006/0023
7Allergy Department, Hospital General La Mancha Centro, Alcázar de San Juan, Ciudad Real, Spain
8Allergy Department, Hospitales Universitarios Santa María y Arnau de Vilanova, IRB Lleida, Lleida, Spain
9Preventive Medicine Department, Hospital Universitario Clínico San Carlos, IdISSC, Madrid, Spain
10Allergy Department, Hospital Universitario Reina Sofía, Córdoba, Spain, Allergy Network ARADyAL RD16/0006/0018, Instituto de Salud Carlos III, Madrid; Instituto Maimónides de Investigación Biomédica de Córdoba, Córdoba, Spain


Key words: Allergy to Hymenoptera. Quality of life. Hymenoptera stings. Large local reactions. Systemic reaction.


Reactions to Hymenoptera venom usually produce pain, pruritus, erythema, and mild inflammation at the site of the sting. Some patients present a large local reaction (LLR), which leads to inflammation greater than 10 cm in diameter and lasts for between 24 hours and 5-10 days [1].

Quality-of-life questionnaires are useful tools in daily clinical practice. In the case of Hymenoptera allergy, Oude Elberink et al [2] developed a quality-of-life questionnaire for patients who experience systemic reactions following Hymenoptera stings (Vespid Allergy Quality of Life Questionnaire [VQLQ]).

Between 2008 and 2015, the Hymenoptera Allergy Committee of the Spanish Society of Allergology and Clinical Immunology (SEIAC) undertook the translation into Spanish and subsequent cultural adaptation of the VQLQ, as well as a cross-sectional and longitudinal validation [3,4]. The questionnaire (HiCaVi) was validated in patients allergic to Hymenoptera venom [5].

Marcela Valverde-Monge
Allergy Department, University Hospital Fundación Jiménez Díaz
Avenida Reyes Católicos, 2
28040 Madrid, Spain
E-mail: marcela.valverde@quironsalud.es

Manuscript received October 31, 2020; accepted for publication February 10, 2021.